Abivax SA ABVX
EURONEXT · France · Health Technology
€84.15-3.65 (-4.16%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics
ABIVAX Société Anonyme (ENXTPA:ABVX) has just paired deeper operating cash use and wider losses with fresh leadership hires and extended funding, creating a complex backdrop for anyone tracking the stock today. Recent moves have come against a tougher tape for ABIVAX Société Anonyme, with the share price down 28.78% year to date and 15.91% over 30 days, even as the 1 year total shareholder return of 16.50% and the very large 3 year total shareholder return of 446.00% point to longer term...
ABIVAX Société Anonyme (ENXTPA:ABVX) has appointed a new Chief Medical Officer and a new Chief Technical Officer. The fresh leadership roles are focused on medical strategy, product development and technical operations across Abivax SA's pipeline. The appointments are intended to support the firm's efforts around clinical programs and preparation for potential commercialization activities. The appointment of a new Chief Medical Officer and Chief Technical Officer should not be the only...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.